AFR Article linked from Botanix facebook pageBotanix Pharmaceuticals, which develops treatments for skin infections and diseases, is one example of a company with assets in late-stage development which investors view as less risky than more novel therapies.
“You have to accept and embrace the fact you are going to step on land mines now and again, otherwise you miss the good ones,” says Hunter. “It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”
He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.
— Rory Hunter, SG Hiscock
AFR Article linked from Botanix facebook pageBotanix...
-
- There are more pages in this discussion • 487 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $1.255M | 3.601M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 206282 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 316320 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |